文献速递造血干细胞移植与细胞治疗白血病

异基因造血干细胞移植多预后评分的外部验证与比较

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2019-01-01

该研究在528例异基因造血干细胞移植受者中外部验证并比较8种常用预后评分系统的区分能力,急性髓系白血病为主要移植指征(44%),46%患者为同胞全合供者。多数模型可将患者分为高低风险组,但2年总生存AUC介于0.55至0.64之间,区分能力有限。rPAM与PAM在所有结局中预测能力最强,EASIx对非复发死亡2年AUC为0.65,但对复发无预测价值(2年AUC 0.53)。

要点

  • 8种评分系统多数可区分高低风险组,但2年总生存AUC仅0.55–0.64,区分能力有限。
  • rPAM(AUC 0.64)与PAM(AUC 0.63)在所有结局中预测能力最强。
  • EASIx对非复发死亡2年AUC 0.65,但对复发2年AUC 0.53无预测价值。

核心结论

  • allo-HSCT预后评分系统可用于风险分层,但个体预测仍具挑战,因评分区分能力有限。

研究设计与样本

  • 对528例allo-HSCT受者进行外部验证,比较8种常用预后评分系统的性能。

主要发现

  • 急性髓系白血病为最主要移植指征(44%),46%患者有同胞全合供者。
  • 2年总生存AUC:rPAM 0.64、PAM 0.63、rDRI 0.62、EASIx 0.60、EBMT/HCT-CI 0.58、EBMT 0.58、Comorbidity-Age 0.58、HCT-CI 0.55。
  • rPAM与PAM在所有结局中预测能力最强,为综合患者、疾病和移植信息的模型。
  • EASIx对非复发死亡2年AUC为0.65,对复发2年AUC为0.53。

关键数值与推荐

  • 2年总生存AUC范围0.55–0.64,AUC 0.5为随机、1.0为完美预测。

临床怎么用

  • allo-HSCT预后评分系统可用于风险分层,但个体预测仍具挑战。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical decisions in allogeneic hematopoietic stem cell transplantation (allo-HSCT) are supported by the use of prognostic scores for outcome prediction. Scores vary in their features and in the composition of development cohorts. We sought to externally validate and compare the performance of 8 commonly applied scoring systems on a cohort of allo-HSCT recipients. Among 528 patients studied, acute myeloid leukemia was the leading transplant indication (44%) and 46% of patients had a matched sibling donor. Most models successfully grouped patients into higher and lower risk strata, supporting their use for risk classification. However, discrimination varied (2-year overall survival area under the receiver operating characteristic curve [AUC]: revised Pretransplantation Assessment of Mortality [rPAM], 0.64; PAM, 0.63; revised Disease Risk Index [rDRI], 0.62; Endothelial Activation and Stress Index [EASIx], 0.60; combined European Society for Blood and Marrow Transplantation [EBMT]/Hematopoietic Cell Transplantation-specific Comorbidity Index [HCT-CI], 0.58; EBMT, 0.58; Comorbidity-Age, 0.58; HCT-CI, 0.55); AUC ranges from 0.5 (random) to 1.0 (perfect prediction). rPAM and PAM, which had the greatest predictive capacity across all outcomes, are comprehensive models including patient, disease, and transplantation information. Interestingly, EASIx, a biomarker-driven model, had comparable performance for nonrelapse mortality (NRM; 2-year AUC, 0.65) but no predictive value for relapse (2-year AUC, 0.53). Overall, allo-HSCT prognostic systems may be useful for risk stratification, but individual prediction remains a challenge, as reflected by the scores' limited discriminative capacity.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Shouval R, Fein JA, Shouval A, et al. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019. PMID: 31221661. doi:10.1182/bloodadvances.2019032268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。